ReviewJournal of vector borne diseases
Epidemiology, drug resistance, and pathophysiology of
Review in Journal of vector borne diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of MIP-1α and MIP-1β Chemokines in Malaria in Relation to Disease Severity.Medicina (Kaunas, Lithuania) · 2025Pooled it
- A systematic review and meta-analysis of blood level of MCP-1/CCL-2 in severe and uncomplicated malaria.Scientific reports · 2024Pooled it
- Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.Malaria journal · 2024Trial
- Pediatric malaria in a non-endemic European setting: clinical patterns, laboratory markers, and the ambiguous role of immunity.Infection · 2026Article
- Anti-GPI scFv as a Promising Tool for Intervention Against Cerebral Malaria in Mice.International journal of molecular sciences · 2026Article
- Article
- Plasmodium vivax congenital and neonatal malaria with atypical presentation in Western Ethiopia: four cases highlighting diagnostic pitfalls.Malaria journal · 2026Article
- Genetic polymorphisms of merozoite surface protein-1 ICB 5-6 in Vietnamese Plasmodium vivax isolates.Parasites, hosts and diseases · 2026Article
- Genetic characterization ofLancet regional health. Americas · 2025Article
- Evolution of tandem repeats in putative circumsporozoite protein to enhance its function: A recent and exclusive event inCurrent research in microbial sciences · 2025Article
- Plasmodium Vivax in a Healthy, Young Immigrant Male.Cureus · 2024Article
- Prospective study of malaria in pregnancy, placental and congenital malaria in Northwest Colombia.Malaria journal · 2024Article
- Comparing malaria risk exposure in rural Cambodia population using GPS tracking and questionnaires.Malaria journal · 2024Article
- Stratification and Adaptation of Malaria Control Interventions in Chad.Tropical medicine and infectious disease · 2023Article
- Role of Human Twin Studies to Identify Genetic Linkage of Malaria Pathogenesis and Outcomes.The American journal of tropical medicine and hygiene · 2023Article
- Analysis of the relapse of imported Plasmodium vivax and Plasmodium ovale in five provinces of China.Malaria journal · 2023Article
- How can the complex epidemiology of malaria in India impact its elimination?Trends in parasitology · 2023Review
- Supervised administration of primaquine may enhance adherence to radical cure forThe Lancet regional health. Southeast Asia · 2023Review
- Clinical and Parasitological Profiles of Gestational, Placental and Congenital Malaria in Northwestern Colombia.Tropical medicine and infectious disease · 2023Article
- Immunological characterization of a VIR protein family member (VIR-14) in Plasmodium vivax-infected subjects from different epidemiological regions in Africa and South America.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Malaria, caused by the protozoan parasites of the genus Plasmodium, is a major health problem in many countries of the world. Five parasite species namely, Plasmodium falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi, cause malaria in humans. Of these, P. falciparum and P. vivax are the most prevalent and account for the majority of the global malaria cases. In most areas of Africa, P. vivax infection is essentially absent because of the inherited lack of Duffy antigen receptor for chemokines on the surface of red blood cells that is involved in the parasite invasion of erythrocytes. Therefore, in Africa, most malaria infections are by P. falciparum and the highest burden of P. vivax infection is in Southeast Asia and South America. Plasmodium falciparum is the most virulent and as such, it is responsible for the majority of malarial mortality, particularly in Africa. Although, P. vivax infection has long been considered to be benign, recent studies have reported life-threatening consequences, including acute respiratory distress syndrome, cerebral malaria, multi-organ failure, dyserythropoiesis and anaemia. Despite exhibiting low parasite biomass in infected people due to parasite's specificity to infect only reticulocytes, P. vivax infection triggers higher inflammatory responses and exacerbated clinical symptoms than P. falciparum, such as fever and chills. Another characteristic feature of P. vivax infection, compared to P. falciparum infection, is persistence of the parasite as dormant liver-stage hypnozoites, causing recurrent episodes of malaria. This review article summarizes the published information on P. vivax epidemiology, drug resistance and pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.